Candel Therapeutics (CADL) Cash from Financing Activities (2020 - 2025)

Candel Therapeutics' Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $43.9 million for Q4 2025.

• In Q4 2025, Cash from Financing Activities fell 52.24% year-over-year to $43.9 million; the TTM figure through Dec 2025 stood at $56.1 million (down 40.5% YoY), while the FY2025 annual figure was $56.1 million, down 40.5% from the prior year.
• Cash from Financing Activities came in at $43.9 million for Q4 2025 at Candel Therapeutics, up from -$3.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $91.9 million in Q4 2024 to a low of -$3.4 million in Q3 2025.
• A 5-year average of $16.1 million and a median of $333000.0 in 2021 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities plunged 436.11% in 2023 and surged 76061.16% in 2024, its largest moves.
• Candel Therapeutics' Cash from Financing Activities stood at $71.4 million in 2021, then slumped by 99.95% to $36000.0 in 2022, then slumped by 436.11% to -$121000.0 in 2023, then soared by 76061.16% to $91.9 million in 2024, then tumbled by 52.24% to $43.9 million in 2025.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $43.9 million, -$3.4 million, and $17.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison